Objective-We sought to develop a murine model to examine the antithrombotic and antiinflammatory functions of human thrombomodulin in vivo. Methods and Results-Knock-in mice that express human thrombomodulin from the murine thrombomodulin gene locus were generated. Compared with wild-type mice, human thrombomodulin knock-in mice exhibited decreased protein C activation in the aorta (PϽ0.01) and lung (PϽ0.001). Activation of endogenous protein C following infusion of thrombin was decreased by 90% in knock-in mice compared with wild-type mice (PϽ0.05). Carotid artery thrombosis induced by photochemical injury occurred more rapidly in knock-in mice (12Ϯ3 minutes) than in wild-type mice (31Ϯ6 minutes; PϽ0.05). No differences in serum cytokine levels were detected between knock-in and wild-type mice after injection of endotoxin. When crossed with apolipoprotein E-deficient mice and fed a Western diet, knock-in mice had a further decrease in protein C activation but did not exhibit increased atherosclerosis.
T hrombomodulin is an endothelial cell-surface thrombin receptor that modulates hemostasis and inflammation. [1] [2] [3] When bound to thrombomodulin, thrombin efficiently catalyzes production of activated protein C (APC), a clinically important endogenous anticoagulant. APC downregulates coagulation by proteolytically inactivating factors Va and VIIIa. In addition to its anticoagulant effects, APC inhibits endothelial inflammatory and cell death pathways 4 through a mechanism that involves protease activated receptor-1 and the endothelial protein C receptor. [5] [6] [7] Thrombomodulin also modulates inflammation independently of APC, possibly by activating antiinflammatory pathways through its N-terminal lectin domain, 8 -10 negatively regulating complement, 11 or by facilitating the activation of thrombin-activatable fibrinolysis inhibitor, a procarboxypeptidase that may modulate both fibrinolysis and complement-mediated inflammation. 2 Several murine models of altered thrombomodulin gene structure have been developed. Homozygous deletion of the murine thrombomodulin gene results in intrauterine lethality before embryonic day (E) 10.5. 12 The mechanism of embry-onic death of thrombomodulin-null embryos is related to thrombin-induced growth arrest of trophoblast cells. 13 Embryonic development is not impaired in mice expressing thrombomodulin mutants with deletions of the C-terminal cytoplasmic or N-terminal lectin domains. 8, 14 Embryonic development also occurs normally in mice with a thrombomodulin mutation (TM ⌬Pro ) that markedly reduces protein C activation and predisposes mice to thrombosis during hypoxia. 15 This observation suggests that low levels of APC are sufficient for normal embryogenesis and placental development.
Because of interspecies differences in thrombomodulin structure and function, current murine models provide only limited insights into the pathophysiological role of human thrombomodulin in vivo. We therefore sought to develop knock-in mice that express human thrombomodulin in the absence of murine thrombomodulin and to determine whether such mice can be used to investigate the function of human thrombomodulin under pathophysiological conditions in vivo. Our results indicate that mice expressing human throm-bomodulin from the murine thrombomodulin gene locus are partially protected from embryonic lethality and have normal postnatal development and survival. Compared with wildtype mice, human thrombomodulin knock-in mice have a prothrombotic phenotype characterized by decreased protein C activation and enhanced susceptibility to experimental thrombosis, but they do not exhibit impaired systemic antiinflammatory responses or enhanced susceptibility to atherosclerosis. These findings reveal differential species-specific effects of murine and human thrombomodulin in regulating thrombosis versus inflammation, and they demonstrate that the human thrombomodulin knock-in mouse is an instructive model for investigating the pathophysiological role of human thrombomodulin in vivo.
Methods

Generation of Human Thrombomodulin Knock-In Mice
Two separate lines of human thrombomodulin knock-in mice, designated Hn and Hthm, were generated by targeted replacement of the murine thrombomodulin (Thbd) gene with the homologous gene segment containing the human thrombomodulin (THBD) coding sequence (for details, see Supplemental Methods and Supplemental Figure I , available online at http://atvb.ahajournals.org). Animal protocols were approved by the University of North Carolina or University of Iowa animal care and use committee.
Generation of Apoe؊/؊ Hthm/Hthm Mice
Apolipoprotein E (Apoe)-null mice 16 on the C57BL/6 background were obtained from the Jackson Laboratory (Bar Harbor, ME) and crossbred with Hthm/ϩ mice for 2 generations to generate littermate ApoeϪ/Ϫ mice that were either Hthm/Hthm or ϩ/ϩ at the thrombomodulin locus. Starting at 3 weeks of age, the mice were fed either a control diet (LM485, Harlan Teklad, Madison, WI) or high-fat Western diet (TD003159, Harlan Teklad) containing 20.3% fat. Experimental procedures were performed on male mice at 24 weeks of age. Blood from anesthetized mice was collected by cardiac puncture into EDTA (final concentration, 5 mmol/L), and plasma cholesterol was measured using the Infinity Cholesterol Reagent kit (Thermo Electron Corp, Louisville, CO).
Morphometric Analysis of Atherosclerotic Lesions
Morphometric analysis of aortic sinus atherosclerotic lesion area was performed as described previously. 17 Briefly, hearts embedded in paraffin were sectioned at 8-m serial intervals through the entire aortic sinus. The sections were stained by the Verhoeff-van Gieson method. Cross-sectional lesion area was calculated using the mean value of 5 sections, each 80 m apart, beginning at the aortic valve leaflets and spanning 320 m.
Measurement of Thrombomodulin mRNA by Quantitative Polymerase Chain Reaction
Total RNA was isolated from lung, heart, or kidney of male mice using Trizol reagent. RNA was treated with DNase I to remove contaminating genomic DNA and then reverse transcribed using TaqMan reverse transcriptase reagents and random hexamer primers. Real-time polymerase chain reaction was performed using a 7700HT sequence detection system (Applied Biosystems) as described previously. 18 Primers and probes were designed using Primer Express software (Applied Biosystems) to be specific for either murine thbd (forward, ATTTCCATTGCCAGCCTGTC; reverse, TGTACTC-CAGCTCTGCACGA) or human THBD (forward, ATCTCCATCGC-GAGCCTGTG; reverse, TGTACTCCATCTTGGCCCTG). A common probe (Fam-CGCCCTGCTTCTTGCGCAGGT-Tamra) was used for both murine and human products. Total amounts of thrombomodulin transcripts in Hthm/Hthm and ϩ/ϩ mice were deter-mined using a probe/primer set that detects regions common to the mouse and human transcripts (forward, GACAGC-CCAGTTTCTTCCAA; reverse, TCTGGGATCTCCGCTG-TATT; probe, Fam-CCACCTCCGCCCAGTTGTCCAG-Tamra). Data were analyzed using the comparative threshold cycle (⌬⌬C T ) method, 19 with ␤-actin as the comparator, using Sequence Detection software, version 1.6.3 (Applied Biosystems).
Immunohistochemistry
Sections of formalin-fixed, paraffin-embedded lung or tail from adult mice were deparaffinized, and endogenous peroxidase activity was quenched with hydrogen peroxide. Sections were blocked with Power Block (Biogenex, San Ramon, CA) and stained with a 1:50 dilution of mouse monoclonal anti-human thrombomodulin antibody (DakoCytomation, Carpenteria, CA) in PBS. Labeled streptavidin biotin II linker-horseradish peroxidase (DakoCytomation) was applied, and staining was visualized with diaminobenzidine (DakoCytomation). Sections were counterstained with Harris hematoxylin without acid.
Thrombomodulin Antigen
Lung lysates were prepared by homogenization in 0.02 mol/L Tris-HCl, 0.1 mol/L NaCl, 2% Triton X-100 (pH 8.0) as described. 20 Human thrombomodulin antigen was measured by ELISA (Asserachrom Thrombomodulin, Diagnostica Stago, Franconville, France). To measure mouse thrombomodulin antigen, immunoassay plates (Nunc-Immuno plate, PolySorp surface, flat bottom, Nalge Nunc International, Rochester, NY) were coated overnight at 4°C with 1 g per well of polyclonal goat anti-mouse thrombomodulin (R&D Systems, Inc, Minneapolis, MN) in 20 mmol/L carbonate (pH 9.2), 0.02% sodium azide. After being washed 3 times, wells were blocked with 1% bovine serum albumin (Research Products International Corp, Prospect, IL) in 50 mmol/L Tris-HCl (pH 7.4), 150 mmol/L NaCl. Lung lysate samples (40 g of protein per well) or recombinant mouse thrombomodulin (R&D Systems) standard samples were added and incubated for 1 hour at room temperature followed by washing. Monoclonal rat anti-mouse thrombomodulin (0.2 g/well, R&D Systems) was added and incubated for 1 hour at room temperature. After 3 additional washes, anti-rat IgG-alkaline phosphatase conjugate antibody (0.064 g/well, Sigma-Aldrich, St Louis, MO) was added and incubated for 1 hour at room temperature. After 3 additional washes, para-nitrophenol phosphate substrate (Sigma-Aldrich) was added, and color development was monitored at 405 nm in a 96-well plate reader (Spectra Max 190, Molecular Devices, Woburn, MA). The standard curve was linear over a range of 0.1 to 2.0 nmol/L recombinant mouse thrombomodulin. No cross-reactivity with recombinant human thrombomodulin was detected at concentrations up to 4 nmol/L. The total protein concentration of lung lysates was measured using a modified Bradford assay (Bio-Rad Laboratories, Richmond, CA).
Protein C Activation
Activation of exogenous protein C by thrombin was measured in freshly isolated rings of proximal aorta (1.0 mm in length) or in lung lysates using a 2-stage assay described previously. 20, 21 Activation assays were performed using either 2.6 nmol/L human thrombin and 150 nmol/L human protein C 20 or 2.6 nmol/L murine thrombin (Hematologic Technologies, Essex Junction, VT) and 150 nmol/L murine protein C. 22 Reference curves were generated using rabbit lung thrombomodulin (American Diagnostica, Stamford, CT). One unit of activity was defined as the amount of APC generated in the presence of 1.0 nmol/L rabbit thrombomodulin.
Activation of endogenous protein C was measured in response to infusion of human thrombin in adult mice. Mice anesthetized with sodium pentobarbital (70 -90 mg/kg) were secured in a supine position under a dissecting microscope and ventilated mechanically with room air and supplemental oxygen as described previously. 21, 23 A heating pad was used to maintain body temperature at 36°C to 37°C. Human thrombin (Hematologic Technologies) (40 U/kg) or saline was rapidly infused into the right cardiac ventricle in a total volume of 100 L. After 10 minutes, blood was collected by cardiac puncture into a 1/10th volume of 0.1 mol/L sodium citrate containing 0.5 mol/L benzamidine. The concentration of murine APC in citrate/benzamidine-treated plasma was measured as described previously 24 and reported as percentage of APC in a pool of normal mouse plasma. For experiments performed with ApoeϪ/Ϫ Hthm/ Hthm mice, murine APC was measured using an enzyme capture assay. Citrate-anticoagulated plasma samples containing 30 mmol/L benzamidine were added to Nunc MaxiSorp plates (Fisher Scientific, Pittsburgh, PA) coated with 5 g/mL anti-mouse APC (AMGDPC 1587), a generous gift from Charles Esmon (Oklahoma Medical Research Foundation, Oklahoma City, OK). The activity of bound APC was determined by incubation for 24 hours at 37°C with Spectrozyme PCa (American Diagnostica), followed by acid quenching and determination of absorbance using a microplate reader (Spectra Max 190, Molecular Devices). Mouse APC (Hematologic Technologies) was used to standardize the assay.
Direct Anticoagulant Activity
To measure the direct anticoagulant activity of thrombomodulin, lung lysates were incubated with 1 nmol/L human ␣-thrombin (HT3054, Enzyme Research, South Bend, IL) and bovine fibrinogen (1 mg/mL, Sigma-Aldrich), and the time to clot formation was measured using a fibrometer (BBL FibroSystem, Becton Dickinson, Franklin Lakes, NJ).
Glycosaminoglycan Hydrolysis
To determine the effect of glycosaminoglycan (GAG) on thrombomodulin activity, lung lysates were incubated for 16 hours at 37°C with or without chondroitin sulfate ABC lyase (Seikagaku America, Falmouth, MA) at a final concentration of 0.2 U/mg protein in 50 mmol/L Tris-HCl containing 100 mmol/L NaCl, 0.5 mmol/L sodium acetate, leupeptin (20 g/mL), pepstatin (10 g/mL), and 2.5 mmol/L o-phenanthroline, pH 8.0. The reaction was stopped by incubating the solution at 90°C for 1 minute. To control for the efficiency of chondroitin sulfate lyase activity, a chondroitin sulfatecontaining proteoglycan (aggrecan) from rat chondrosarcoma 25 was added to the chondroitin sulfate lyase-lung lysate mixtures. The mixtures were electrophoresed using 7.5% SDS-PAGE and stained with Coomassie Blue to detect a characteristic 94-kDa aggrecan peptide devoid of GAG. 25 Protein C activation and direct anticoagulant activity assays were then performed using chondroitin sulfate lyase-treated or control lung lysates.
Carotid Artery Thrombosis
Carotid artery thrombosis was induced by photochemical injury as described. 21, 23 Mice anesthetized with sodium pentobarbital (70 -90 mg/kg) were ventilated mechanically with room air and supplemental oxygen. Blood flow in the right carotid artery was measured with a 0.5 PSB Doppler flow probe (Transonic Systems, Ithaca, NY). To induce endothelial injury, the right common carotid artery was transilluminated continuously with a 1.5-mV, 540-nm green laser (Melles Griot, Carlsbad, CA) from a distance of 6 cm, and Rose Bengal (25-50 mg/kg) was injected via a femoral vein catheter. Blood flow was monitored continuously for 90 minutes or until stable occlusion occurred. Stable occlusion was defined as the time at which blood flow remained absent for Ն10 minutes.
Response to Endotoxin
Endotoxin (Escherichia coli bacterial lipopolysaccharide [LPS] serotype 055:B5) was purchased from Sigma-Aldrich. Mice were injected intraperitoneally with 8 mg/kg LPS or saline in a volume of 100 L. After 4 hours, serum was isolated for measurement of interleukin-6, interleukin-1␤, and tumor necrosis factor-␣ by Quantikine immunoassay kits (R&D Systems). Plasma and serum were frozen at Ϫ80°C until they were assayed.
Statistical Analyses
Comparisons between mouse genotypes were performed using the unpaired 2-tailed Student t test or 1-way ANOVA. Occlusion times were compared with the Mann-Whitney rank sum test. Viability data were analyzed using the 2 test. Statistical significance was defined as a probability value less than 0.05. Values are reported as meanϮSE. Except where indicated, all statistical comparisons were performed between littermates, and all experimental groups included both female and male mice.
Results
Generation and Viability of Human Thrombomodulin Knock-In Mice
Two separate lines of human thrombomodulin knock-in mice, designated Hn and Hthm, were generated by targeted replacement of the murine Thbd gene with the homologous gene segment containing the human THBD coding sequence (Supplemental Figure I ). The Hn line contained a loxP-flanked (floxed) neomycin resistance gene within the thrombomodulin 3Ј untranslated region. The Hthm line was generated by crossbreeding Hn/ϩ mice with transgenic mice expressing Cre recombinase 26 to excise the neomycin resistance gene.
In both the Hn and Hthm lines, the gross appearance of weaned heterozygous and homozygous human thrombomodulin knock-in mice was normal, and no abnormalities in organ morphology or histology were observed. However, the number of viable homozygous Hn/Hn or Hthm/Hthm mice produced from heterozygous matings was decreased from expected mendelian frequencies ( Supplemental Tables I and  II) . Homozygous Hn/Hn mice represented only 5% of weaned offspring (PϽ0.05 versus the expected Mendelian frequency of 25%). The frequency of homozygous Hthm/Hthm offspring at weaning (14%) was greater than for Hn/Hn homozygotes (PϽ0.001) but was still less than the expected mendelian frequency (PϽ0.05). There were no significant differences in the frequencies of homozygous Hthm/Hthm or Hn/Hn offspring at weaning between mice on a 129/SvEv inbred background versus mice on a mixed background of 129/SvEv and C57BL/6. Hn/Hn and Hthm/Hthm mice that survived weaning exhibited normal growth and survival. The mean weights of Hn/Hn and Hthm/Hthm mice between 12 and 18 months of age did not differ from ϩ/ϩ mice (data not shown).
Because mice with complete deficiency of thrombomodulin uniformly die before day 10 of embryogenesis, 12 we sought to determine whether the decreased viability of human thrombomodulin knock-in mice also was due to early embryonic lethality. The frequencies of Hn/Hn and Hthm/Hthm fetuses isolated from heterozygous matings on E10.5 were 16% and 23%, respectively ( Supplemental Tables I and II) , which suggests that early embryonic viability is relatively normal in human thrombomodulin knock-in mice. On E17.5, the frequencies of Hn/Hn and Hthm/Hthm fetuses had decreased to 6% and 13%, respectively, quite similar to those observed at weaning. These findings suggest that homozygous replacement of the murine thrombomodulin allele with the Hn or Hthm alleles resulted in the partial loss of viability between E10.5 and E17.5. This effect on viability was more severe for Hn/Hn mice than for Hthm/Hthm mice.
Expression of Thrombomodulin mRNA
Levels of total (murine plus human) thrombomodulin mRNA were measured in lung and heart isolated from adult ϩ/ϩ, Hthm/Hthm, and Hn/Hn mice using real-time polymerase chain reaction primers that detect both murine and human transcripts ( Table 1 ). The levels of total thrombomodulin mRNA in the lung of Hthm/Hthm and Hn/Hn mice were not significantly different from those in ϩ/ϩ mice. In the heart, the levels of total thrombomodulin mRNA were similar in ϩ/ϩ and Hthm/Hthm mice, but they were 50% lower in Hn/Hn mice than in ϩ/ϩ mice (PϽ0.05).
Levels of individual murine thrombomodulin and human thrombomodulin transcripts were measured in ϩ/ϩ, Hthm/ϩ, and Hn/ϩ mice using species-specific real-time polymerase chain reaction primers ( Table 2 ). Levels of murine thrombomodulin mRNA in the lung, heart, and kidney of Hthm/ϩ mice were 50% to 60% lower than levels measured in ϩ/ϩ mice (PϽ0.05). Levels of murine thrombomodulin mRNA in the lung, heart, and kidney of Hn/ϩ mice were 40% to 65% lower than those in ϩ/ϩ mice (PϽ0.05). These findings indicate that the presence of the targeted allele in heterozygous Hthm/ϩ or Hn/ϩ mice does not have a major influence on thrombomodulin expression from the wild-type allele. As expected, human thrombomodulin mRNA was not detected in ϩ/ϩ mice. The relative expression of human thrombomodulin mRNA in the lung and kidney was similar in Hthm/ϩ and Hn/ϩ mice. In the heart, there was a trend toward lower levels of human thrombomodulin mRNA in Hn/ϩ mice compared with Hthm/ϩ mice (8Ϯ2 versus 15Ϯ4%; Pϭ0.24), a finding that is consistent with the lower level of total thrombomodulin mRNA in the heart of Hn/Hn mice ( Table 1) .
Expression of Human Thrombomodulin Protein
Expression of human thrombomodulin protein in Hthm/ϩ and Hthm/Hthm mice was demonstrated by immunohistochemistry and ELISA (Figure 1 ). Immunohistochemical staining of tail cross-sections using a monoclonal anti-human thrombomodulin antibody was strongly positive in endothelium and keratinocytes in Hthm/Hthm mice, moderately positive in Hthm/ϩ mice, and negative in ϩ/ϩ mice ( Figure  1A-1C ). This expression pattern is consistent with that observed previously for thrombomodulin in mice and humans. 27, 28 Immunofluorescence staining of lung sections also revealed endothelium-specific staining for human thrombomodulin in Hthm/ϩ and Hthm/Hthm mice, whereas staining for murine thrombomodulin was detected in ϩ/ϩ and Hthm/ϩ mice (Supplemental Figure III) . Colocalization of murine and human thrombomodulin was observed in lung endothelium (Supplemental Figure IV) .
Human thrombomodulin antigen levels measured by ELISA in lung lysates were concordant with immunohistochemical observations ( Figure 1D ). Human thrombomodulin antigen was approximately twice as high in Hthm/Hthm mice compared with Hthm/ϩ mice (Pϭ0.01). Murine thrombomodulin antigen levels measured by ELISA in lung lysates were decreased by approximately 70% in Hthm/ϩ mice compared with ϩ/ϩ mice (PϽ0.01) ( Figure 1E ).
Protein C Activation
Activation of protein C in aortic rings and lung lysates was measured in vitro using human protein C and human thrombin. Generation of APC was similar in aortic rings from ϩ/ϩ and Hthm/ϩ mice (Figure 2A ). APC generation was decreased by 28% in aortic rings from Hn/ϩ mice (PϽ0.05 versus ϩ/ϩ mice), and by approximately 60% in aortic rings from both Hthm/Hthm and Hn/Hn mice (PϽ0.01 versus ϩ/ϩ mice). With lung lysates ( Figure 2B ), generation of APC was decreased by approximately 50% for Hthm/ϩ and Hn/ϩ mice (PϽ0.05 versus ϩ/ϩ mice), 75% for Hthm/Hthm mice (PϽ0.001 versus ϩ/ϩ mice), and 90% for Hn/Hn mice (PϽ0.05 versus ϩ/ϩ mice). To determine whether differences in protein C activation also occurred with murine reagents, activation of murine protein C was measured with lung lysates from ϩ/ϩ, Hthm/ϩ, and Hthm/Hthm mice using murine thrombin. Compared with lysates from ϩ/ϩ mice, lysates from Hthm/ϩ mice generated 52% less APC (PϽ0.05), and lysates from Hthm/Hthm mice generated 86% less APC (PϽ0.001) ( Figure 2C ).
Activation of endogenous murine protein C in vivo was assessed by measuring plasma levels of APC in ϩ/ϩ, Hthm/ϩ, and Hthm/Hthm mice following infusion of saline vehicle or 40 U/kg human thrombin ( Figure 2D ). Compared with infusion of saline, infusion of thrombin produced a 2.7-fold increase in plasma APC concentration in ϩ/ϩ mice (PϽ0.05) but no significant increase in Hthm/ϩ or Hthm/ Hthm mice. The total amount of thrombomodulin mRNA was determined using a probe/primer set that detects regions common to the murine and human transcripts. All mice were on an inbred 129/SvEv background and were studied at 4 to 6 mo of age. Data are reported as a percentage of the total amount of thrombomodulin mRNA in the lung of ϩ/ϩ mice. Values represent meanϮSE (nϭ4 -5 in each group). *PϽ0.05 vs ϩ/ϩ mice. Levels of individual murine thrombomodulin and human thrombomodulin transcripts were measured using species-specific real-time polymerase chain reaction primers. All mice were on an inbred 129/SvEv background and were studied at 4 to 6 mo of age. Data are reported as a percentage of murine thrombomodulin mRNA in the lung of ϩ/ϩ mice. Values are meanϮSE (nϭ4 -7 in each group). TM indicates thrombomodulin mutation. *PϽ0.05 vs ϩ/ϩ mice.
Effect of GAG Hydrolysis on Thrombomodulin Activity
To determine whether the decreased thrombomodulin activity of human thrombomodulin knock-in mice was caused by differential effects of GAG attachment to thrombomodulin, lung lysates from ϩ/ϩ or Hthm/Hthm mice were incubated with chondroitin sulfate ABC lyase before protein C activation or direct anticoagulant activity assays were performed. The protein C activation activity of thrombomodulin in lung lysates from ϩ/ϩ or Hthm/Hthm mice was not significantly affected by treatment with chondroitin sulfate lyase (Supplemental Figure VA) . In contrast, the direct anticoagulant activity of thrombomodulin (ie, the ability of thrombomodulin to directly inhibit the fibrinogen cleaving activity of thrombin), which is highly sensitive to its GAG content, 29 was decreased by approximately 40% after GAG hydrolysis in both the ϩ/ϩ and Hthm/Hthm samples (Supplemental Figure VB) . These results suggested that GAG attachment contributes equivalently to the direct anticoagulant activity of murine and human thrombomodulin expressed in mouse lung.
Carotid Artery Thrombosis
The time to thrombotic occlusion of the carotid artery after photochemical injury was measured in ϩ/ϩ, Hthm/ϩ, and Hthm/Hthm mice (Figure 3 ). Occlusion times did not differ between ϩ/ϩ and Hthm/ϩ mice, but the mean time to stable occlusion was decreased by more than 60% in Hthm/Hthm mice (12Ϯ3 minutes) compared with ϩ/ϩ mice (31Ϯ6 minutes) (PϽ0.05).
Response to Endotoxin
The inflammatory response to intraperitoneal injection of a sublethal dose of 8 mg/kg E. coli LPS was determined by measurement of serum cytokine levels in ϩ/ϩ and Hthm/ Hthm mice 4 hours after LPS administration. Serum levels of interleukin-6 ( Figure 4A ), interleukin-1␤ ( Figure 4B) , and tumor necrosis factor-␣ ( Figure 4C ) all increased significantly and equivalently after LPS administration in ϩ/ϩ and Hthm/Hthm mice (PϽ0.05 versus saline).
Phenotype of Apoe؊/؊ Hthm/Hthm Mice
To determine the effects of hypercholesterolemia in human thrombomodulin knock-in mice, ApoeϪ/Ϫ mice were crossbred with Hthm/ϩ mice for 2 generations to generate littermate ApoeϪ/Ϫmice that were either Hthm/Hthm or ϩ/ϩ at the thrombomodulin locus. Starting at 3 weeks of age, male mice were fed either a control diet or high-fat Western diet until they were studied at 24 weeks of age. Compared with the control diet, the high-fat diet produced a similar 2-fold increase in plasma total cholesterol levels in ApoeϪ/Ϫ and ApoeϪ/Ϫ Hthm/Hthm mice (PϽ0.01) ( Figure 5A ). The high-fat diet also produced similar increases in cross- sectional atherosclerotic lesion area, measured in the aortic sinus, compared with the control diet in ApoeϪ/Ϫ and ApoeϪ/Ϫ Hthm/Hthm mice (PϽ0.01) ( Figure 5B ). Following infusion of thrombin, circulating plasma levels of APC were significantly lower in ApoeϪ/Ϫ Hthm/Hthm mice compared with littermate ApoeϪ/Ϫ mice fed either the control or high-fat diets (PϽ0.01) ( Figure 5C ). Notably, the amount of circulating APC generated in ApoeϪ/Ϫ Hthm/ Hthm mice was significantly lower with the high-fat diet than the control diet (PϽ0.05). Finally, the time to stable thrombotic occlusion of the carotid artery after photochemical injury was decreased markedly in ApoeϪ/Ϫ or ApoeϪ/Ϫ Hthm/Hthm mice fed the high-fat diet (PϽ0.05) ( Figure 5D ), confirming that hypercholesterolemia induces a prothrombotic phenotype in mice expressing either murine or human thrombomodulin. 
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Discussion
We generated knock-in mice that express human thrombomodulin in the absence of murine thrombomodulin. Human thrombomodulin knock-in mice exhibited a prothrombotic phenotype, with decreased activation of protein C in vivo following thrombin infusion and an accelerated thrombotic response to carotid artery injury. Interestingly, exposure to endotoxin produced identical systemic cytokine responses in wild-type and human thrombomodulin knock-in mice, which suggests that despite their markedly different anticoagulant profiles, mice expressing murine and human thrombomodulin have similar inflammatory responses in vivo. Mice expressing human or murine thrombomodulin also had similar susceptibilities to atherosclerosis when crossed to an apolipoprotein E-deficient background. Interestingly, hypercholesterolemia produced a significant impairment of protein C activation in mice expressing human thrombomodulin, which demonstrates the potential utility of the human thrombomodulin knock-in mouse as a pathophysiological model for the study of human thrombomodulin function in conditions such as atherosclerosis. Expression of human thrombomodulin in place of murine thrombomodulin partially bypassed the uniform embryonic lethality that occurs with complete deficiency of murine thrombomodulin. 12 Approximately 50% of mice homozygous for the Hthm allele and 80% of mice homozygous for the Hn allele died between E10.5 and E17.5 ( Supplemental Table I ). Thrombomodulin is expressed in both trophoblasts and developing endothelium early in embryogenesis. 1 The mechanism of early embryonic death of thrombomodulin-null em-bryos appears to be caused by growth arrest of trophoblast cells. 13 Reconstitution of murine thrombomodulin expression in placental tissue rescues thrombomodulin-null embryos from early embryonic lethality, and reveals a secondary developmental block between days 12.5 and 16.5 that is caused by lack of thrombomodulin expression in endothelium. 13, 30 Our findings suggest that human thrombomodulin can functionally substitute for murine thrombomodulin to bypass the early trophoblast-dependent developmental block but only partially bypass the later, endothelium-dependent developmental block. The more severe embryonic loss in Hn/Hn mice compared with Hthm/Hthm mice may be due to slightly lower expression of human thrombomodulin in some tissues (Table 1) , likely caused by the presence of the neomycin resistance gene within the 3Ј untranslated region of the Hn allele.
Compared with wild-type mice, human thrombomodulin knock-in mice were hypomorphic for thrombomodulin activity and exhibited a prothrombotic phenotype, with a 50% shortening in the time to carotid artery occlusion following photochemical injury. The prothrombotic phenotype of human thrombomodulin knock-in mice contrasts with the antithrombotic phenotype of human thrombomodulin transgenic mice reported recently by Crikis et al. 31 An important distinction between these models is that the transgenic mouse model described by Crikis et al 31 is a thrombomodulin overexpression model in which the human thrombomodulin transgene is expressed in addition to endogenous murine thrombomodulin. Overexpression of (humanϩmurine) thrombomodulin in these mice results in increased APC generation and protection from thrombosis. 31 In contrast, the human thrombomodulin knock-in mouse model reported here is a hypomorphic model in which human thrombomodulin is expressed instead of murine thrombomodulin. Compared with ϩ/ϩ mice, Hthm/Hthm mice had similar levels of thrombomodulin mRNA expression ( Table 1 ) and higher levels of thrombomodulin antigen in the lung (Figure 1) . These findings suggest that the prothrombotic phenotype (decreased protein C activation and enhanced susceptibility to arterial thrombosis) in Hthm/Hthm mice is unlikely to be caused by an alteration in thrombomodulin expression. Instead, the findings suggest that human thrombomodulin may be a less active anticoagulant than murine thrombomodulin in vivo.
We explored the possibility that differences in protein C activation between wild-type and human thrombomodulin knock-in mice may be related to differences in modification by O-linked chondroitin sulfate GAG chains. Thrombomodulin's GAG chains provide secondary thrombin binding sites and enhance its anticoagulant function. 32, 33 Both murine and human thrombomodulin contain GAG attachment consensus sequences within their serine/threonine rich domains. 34 In human thrombomodulin, the primary GAG attachment site is serine 474. 35 Mouse thrombomodulin has a homologous serine attachment site, but the flanking sequence contains a series of 3 acidic residues that may enhance the efficiency of GAG attachment. 36 Despite these sequence differences, when human and murine thrombomodulin were treated with chondroitin sulfate ABC lyase to remove GAG, no significant effects on protein C activation were observed (Supplemental Figure  V) . The direct anticoagulant function of both murine and human thrombomodulin was decreased by GAG removal, but the effects were similar for ϩ/ϩ and Hthm/Hthm mice. These results indicate that GAG attachment plays an equivalent role in the anticoagulant activity of murine and human thrombomodulin and suggest that the prothrombotic phenotype of human thrombomodulin knock-in mice is not due to differential effects of GAG. It is more likely, therefore, that structural changes due to amino acid differences are responsible for the more potent antithrombotic activity of murine compared with human thrombomodulin. It is possible but unlikely that the decreased protein C activation in human thrombomodulin knock-in mice is related to the presence of the Ala455Val polymorphism within the sixth epidermal growth factor domain. This common human thrombomodulin polymorphism has been found to be associated with arterial thrombosis in some studies, but several large population studies have failed to confirm this association. 37, 38 Several other candidate prothrombotic thrombomodulin mutations have been identified in human subjects with venous or arterial thrombosis, but the clinical significance of these gene variants remains uncertain. [37] [38] [39] Mutations that impair the function of thrombomodulin were recently described in some patients with atypical hemolytic uremic syndrome. 40 The thrombomodulin knock-in approach described in this study could potentially be used to directly examine the pathophysiological consequences of these and other human thrombomodulin gene variants.
Despite considerable progress in defining the role of thrombomodulin and the protein C activation pathway in susceptibility to thrombosis and modulation of inflammatory responses, the impact of this anticoagulant pathway on atherosclerosis is less well understood. 41 Eitzman et al observed accelerated atherogenesis in ApoeϪ/Ϫ mice expressing the murine equivalent of the human factor V Leiden mutation, which confers resistance to APC. 42 Seehaus et al found that expression of a hypomorphic murine thrombomodulin mutation (TM ⌬Pro ) in ApoeϪ/Ϫ mice had paradoxical effects on atherosclerosis; the atherosclerotic lesions were larger but also had histological features suggestive of enhanced plaque stability. 43 These observations raise the question of whether human thrombomodulin confers protection from or susceptibility to atherosclerosis. Our findings indicate that mice expressing human or murine thrombomodulin have similar susceptibilities to atherosclerosis when crossed to the ApoeϪ/Ϫ background despite their differing anticoagulant activities. The contrasting effects on atherosclerosis of the murine TM ⌬Pro mutant studied by Seehaus et al 43 and human thrombomodulin in our study could be due to a relatively lower anticoagulant activity of the TM ⌬Pro mutant. 15 Alternatively, these findings might suggest that human thrombomodulin has protective effects on atherosclerosis that are independent of its anticoagulant activity. In either case, our results suggest that the human thrombomodulin knock-in mouse may be an informative in vivo model for future studies investigating the role of human thrombomodulin in atherosclerosis and other pathophysiological conditions. A limitation of many mouse models is that there often are species-specific functional differences between human and murine proteins that may alter responses to pathophysiological conditions or pharmacological interventions. The generation of human thrombomodulin knock-in mice is a step toward humanizing the entire protein C system in mice. Such humanization might facilitate the discovery of small molecules that modify the human anticoagulant system and the study of in vivo consequences of such modifications. The current model is limited because only the thrombomodulin gene locus was humanized, and it is not possible to directly compare the functional activities of human versus murine thrombomodulin because of differences in their expression levels. Nevertheless, the availability of this model, as well as other similar models, such as the humanized tissue factor mouse, 44 may enhance the clinical relevance of mouse models of human thrombotic disease.
